Stop parsing PDFs. Get the API. Request Access

AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

Fresenius SE & Co. KGaA

Investor Presentation • May 14, 2011

166_ip_2011-05-14_12ba88d6-507e-42b9-94d3-99375edc9dc7.pdf

Investor Presentation

Open in Viewer

Opens in native device viewer

Annual General Meeting Fresenius SE & Co. KGaA Welcome

May 13, 2011

Agenda

I. Financial Results 2010

II. Share Price Development

III. 1st Quarter 2011 and Outlook

2010 – An Outstanding Year for Fresenius

    • Record sales and earnings – guidance and midterm outlook met or exceeded
  • Double-digit earnings growth in all business segments
  • Excellent growth in intravenously administered drugs in North America
  • Share conversion and change of legal form

US-GAAP

Fresenius Group: Excellent Financial Results

1 Net income attributable to Fresenius SE & Co. KGaA; adjusted for the effects of mark-to-mark accounting of the MEB and the CVR.

Fresenius Group: Midterm Target "15/15" exceeded

US-GAAP

CAGR = Compound annual growth rate

Fresenius SE & Co. KGaA: 18th Consecutive Dividend Increase Proposed

  • Proposed dividend: €0.86 per ordinary share
  • Dividend increase of 15%
  • Total distribution:

€140 m

Fresenius Share Price Development 2010 and 2011

R
l
i
S
h
P
i
P
f
t
e
a
v
e
a
r
e
r
c
e
e
r
o
r
m
a
n
c
e		 S
h
P
i
a
r
e
r
c
e
D
l
t
e
v
e
o
p
m
e
n		 2
0
1
0		 2
0
1
1
3
1.
1
2.
2
0
0
9
1
0
0
=
O
d
in
ie
1
6
0
r
ar
s		 O
d
i
h
r
n
a
r
y
s
a
r
e
:		 %
4
4
+		 %
1
6
+
0
1
5
0
Pr
fe
1
4
e
re
nc
es
1
3
0
D
A
X
1
2
0		 f
h
P
r
e
e
r
e
n
c
e
s
a
r
e
:		 %
2
8
+
1
1
0
1
0
0
9
0		 D
A
X
:		 %
1
6
+		 %
8
+
8
0
3
2.
0
9
3
0
3.
0
3
0.
0
0
3
0.
0
9.
0
3
2.
0
1.
1
1.
1
6.
1
1
1.
1
1

Fresenius Group: Excellent Start into 2011

S
l
a
e
s		 E
B
I
T		 1
N
i
t
e
n
c
o
m
e
Q
/
1
2
0
1
1		 €
3
9
6
2
m
,		 €
5
7
5
m		 €
1
7
0
m
G
h
t
t
t
t
r
o
w
a
c
o
n
s
a
n
t
c
u
r
r
e
n
c
y
r
a
e
s		 7
%		 1
3
%		 3
9
%
G
h
l
t
t
t
r
o
w
a
a
c
u
a
t
c
u
r
r
e
n
c
y
r
a
e
s		 %
9		 %
1
5		 %
4
3

US-GAAP

1 Net income attributable to Fresenius SE & Co. KGaA; adjusted for the effects of mark-to-mark accounting of the MEB and the CVR.

Fresenius Medical Care: 1st Quarter 2011 and Outlook

t
1
Q
2
0
1
1
t
s
u
a
r
e
r
S
l
a
e
s		 \$
S
U
3
0
3
6
m
,
1
N
i
t
e
n
c
o
m
e		 \$
U
S
2
2
1
m
O
l
k
2
t
0
1
1
u
o
o
-----------------------------------------------------
S
l
a
e
s		 \$
U
S
3
0
b
1
n
>
1
i
N
t
e
n
c
o
m
e		 \$
S
U
1
0
7
0
1
0
9
0
m
–
,
,

Midterm Outlook

Sales, growth 6 – 8%

2

US-GAAP

1Net income attributable to Fresenius Medical Care AG & Co. KGaA

2At constant currency

Fresenius Kabi: 1st Quarter 2011 and Outlook

t
1
Q
2
0
1
1
t
s
u
a
r
e
r
S
l
a
e
s		 €
9
6
0
m
E
B
I
T		 €
1
9
7
m
O
l
k
2
0
1
1
t
u
o
o
S
l
a
e
s
h
i
t
g
r
o
o
r
g
a
n
c
w
,		 5
%
>
E
B
I
T
i
m
a
r
g
n		 %
1
9
2
0
–
i
d
O
l
k
M
t
t
e
r
m
o
o
u
S
l
a
e
s
h
i
t
g
r
o
w
o
r
g
a
n
c
,		 0
%
7
1
–
i
E
B
I
T
m
a
r
g
n		 %
1
8
2
0
–

Fresenius Helios: 1st Quarter 2011 and Outlook

Fresenius Vamed: 1st Quarter 2011 and Outlook

t
Q
1
2
0
1
1
s
t
a
r
e
r
u
S
l
a
e
s		 €
1
4
0
m
E
B
I
T		 €
5
m
O
l
k
2
0
1
1
t
o
o
u
S
l
a
e
s
h
t
g
r
o
w
,		 %
5
1
0
–
E
B
I
T
,		 h
t
g
r
o
w		 5
–		 1
0
%

Midterm Outlook

Sales €1 bn by 2014

Fresenius Group: Positive Outlook 2011

h
R
t
e
v
e
n
u
e
g
r
o
w
t
t
t
a
c
o
n
s
a
n
c
u
r
r
e
n
c
y		 %
7
8
–
1
N
i
h
t
t
e
n
c
o
m
e
g
r
o
w
t
t
t
a
c
o
n
s
a
n
c
u
r
r
e
n
c
y		 1
2
1
6
%
–
C
a
p
e
x		 %
f
G
l
5
o
r
o
u
p
s
a
e
s
~

1 Net income attributable to Fresenius SE & Co. KGaA and before special items due to MEB and CVR accounting

Fresenius Group: Where are we Heading Mid term?

Additional growth through small / mid-sized acquisitions

Focus on quality and cost leadership

Mid-term stretch financial goal: Group net income >€1 bn by 2014

Annual General Meeting Fresenius SE & Co. KGaA Thank you for your attention

May, 13 2011

Safe Harbor Statement

This presentation contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. Fresenius does not undertake any responsibility to update the forward-looking statements contained in this presentation.

More from Fresenius SE & Co. KGaA

Declaration of Voting Results & Voting Rights Announcements 2025
Nov 17
Declaration of Voting Results & Voting Rights Announcements 2025
Nov 14
Report Publication Announcement 2025
Nov 6
Quarterly Report 2025
Nov 6
Interim / Quarterly Report 2025
Aug 6
Investor Presentation 2025
Aug 6
Declaration of Voting Results & Voting Rights Announcements 2025
Jul 4
Declaration of Voting Results & Voting Rights Announcements 2025
Jun 20
Governance Information 2025
May 23
Quarterly Report 2025
May 7
View all filings →

Talk to a Data Expert

Have a question? We'll get back to you promptly.